Lincoln Pharma Ltd
NSE: LINCOLN · Pharmaceuticals · sector
₹529.25NSE close 2026-10-26
Key numbers
Market cap₹1,060 cr
Price₹529.25
52w high / low₹770 / ₹440
P/E11.0xSector median 27.9x
P/B1.4xSector median 2.9x
Book value₹378.2
Dividend yield0.34%Sector median 0.48%
ROE13.5%Sector median 11.7%
ROCE16.9%Sector median 12.3%
OPM14.6%Sector median 14.0%
Debt / equity0.01xSector median 0.16x
EV/EBITDA8.1xSector median 18.6x
Interest cover121.3x
Current ratio5.25x
Sales growth 3y+9.6%Sector median +9.6%
Profit growth 3y+6.4%Sector median +13.3%
PEG1.71x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹241 cr vs borrowings ₹4 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 121.3x in the last 12 months.
- Operating cash flow was below net profit in 2 of the last 5 years (FY24, FY23).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 44% of net profit in the last 12 months.
- Debtor days went from 102 (FY24) to 88 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹529.25 on 2026-10-26: -31.3% from the 52-week high, +20.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹922.95 · low ₹456.45
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| EBITDA | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 17.6% | 16.1% | 15.9% | 15.4% | 15.6% | 14.2% | 13.3% | 15.5% |
| Other income | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Net profit | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS (₹) | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
| Revenue YoY | +1.3% | +13.5% | +11.4% | +15.1% | ||||
| Profit YoY | -24.1% | +37.7% | +0.5% | +30.9% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 472 | 510 | 581 | 623 | 671 | 694 |
| EBITDA | 95 | 89 | 100 | 101 | 98 | 101 |
| Net profit | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS (₹) | 34.63 | 36.40 | 46.58 | 41.11 | 43.88 | 48.16 |
| Revenue growth | +8.1% | +13.8% | +7.4% | +7.7% | +10.2% | |
| Profit growth | +5.1% | +28.0% | -11.7% | +6.7% | +11.7% | |
| Dividend / share (₹) | 1.50 | 1.50 | 1.50 | 1.80 | 1.80 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +9.6% | +10.2% | +10.2% |
| Net profit | +6.4% | +7.8% | +11.7% |
| EPS | +6.4% | +7.8% | – |
| Share price | – | -11.8% (2y) | -2.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 502 | 593 | 672 | 758 |
| Borrowings | – | 2 | 1 | 0 | 4 |
| Cash & equivalents | – | 126 | 153 | 196 | 241 |
| Total assets | – | 587 | 700 | 797 | 890 |
| Fixed assets | – | 150 | 179 | 182 | 190 |
| Capital work in progress | – | 7 | 3 | 4 | 5 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 136 | 162 | 166 | 161 |
| Inventory | – | 70 | 77 | 79 | 80 |
| Payables | – | 51 | 72 | 85 | 85 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 76 | 39 | 63 | 93 | 106 |
| Cash from investing | -78 | -37 | -57 | -79 | -98 |
| Cash from financing | -3 | -4 | -5 | -6 | 0 |
| Capex | 46 | 14 | 39 | 19 | 26 |
| Free cash flow | 31 | 25 | 24 | 74 | 80 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 14.5% | 15.7% | 12.3% | 11.6% |
| ROCE % | – | 20.3% | 20.8% | 16.5% | 15.3% |
| Debtor days | – | 98 | 102 | 97 | 88 |
| Inventory days | – | 106 | 101 | 99 | 94 |
| Payable days | – | 77 | 95 | 106 | 100 |
| Cash conversion cycle (days) | – | 127 | 108 | 90 | 82 |
| Working capital days | – | 211 | 223 | 231 | 257 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 49.78% |
| FIIs | 4.55% |
| DIIs | 0.02% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 45.65% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% | 49.78% |
| Promoter group | % |
|---|---|
| Munjal Mahendrabhai Patel | 13.37% |
| Ashish Rajanikant Patel | 10.60% |
| Rajanikant Gulabdas Patel | 3.78% |
| Mahendrabhai Gulabdas Patel | 3.37% |
| Sunmed Corporation Llp | 2.50% |
| Kailashben Mahendrabhai Patel | 2.40% |
| Downtown Travels Llp | 2.37% |
| Hasmukhbhai Ishwarbhai Patel | 1.87% |
| Anand Arvinbhai Patel | 1.66% |
| Shivani Ashish Patel | 1.03% |
| Mansi Munjal Patel | 1.00% |
| Hansaben Arvindbhai Patel | 0.88% |
| Patel Nishitkumar Maheshbhai | 0.77% |
| Dharmisthaben Bhagirath Patel | 0.62% |
| Arvindbhai Gulabdas Patel | 0.55% |
| Public holders above 1% | % |
|---|---|
| Kishor M. Shah | 2.39% |
| Rimo Capital Fund Lp | 1.35% |
| Dheeraj Kumar Lohia | 1.24% |
29,272 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LINCOLN | ₹1,060 cr | 11.0x | 1.4x | 13.5% | 16.9% | 14.6% | +9.6% | 0.34% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-11 | Dividend | Dividend - Rs 1.80 Per Share |
| 2025-09-12 | Dividend | Dividend - Rs 1.80 Per Share |
| 2024-09-13 | Dividend | Dividend - Rs 1.80 Per Share |
| 2023-09-15 | Dividend | Annual General Meeting/Dividend - Rs 1.50 Per Share |
| 2022-09-15 | Dividend | Annual General Meeting/Dividend - Rs 1.50 Per Share |
| 2021-09-16 | Dividend | Dividend - Rs 1.50 Per Share |
| 2020-09-17 | Other | Annual General Meeting |
| 2020-03-05 | Dividend | Interim Dividend - Rs 1.5 Per Share |
| 2019-09-19 | Dividend | Dividend - Rs 1.5 Per Share |
| 2018-09-19 | Dividend | Dividend Rs 1.50 Per Share |
| 2017-09-21 | Dividend | Annual General Meeting/Dividend - Rs 1.20 Per Share |
| 2016-09-23 | Dividend | Annual General Meeting/Dividend - Re 1/- Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | LINCOLN |
| BSE code | 531633 |
| ISIN | INE405C01035 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.